Indo Us Biotech credit ratios

·FMCG & RetailChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
37.037.014.8
30.930.914.6
0.40×0.40×0.19×
0.33×0.33×0.19×
2.18×2.18×0.78×
3.54×1.82×0.77×
7.18×7.18×11.99×
28.7%28.6%15.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

INDOUS₹78.36

Indo Us Biotech Limited

· FMCG & Retail
₹ CrorePeersKOHINOORNATHBIOGENAGRITECHSARVESHWARSUKHJITSREGAALBSHSLGULPOLYMcap ₹157 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Total Debt14.837.037.0
Net Debt14.630.930.9
Total Debt/Equity0.190.400.40
Net Debt/Equity0.190.330.33
Total Debt/EBITDA0.782.182.18
Net Debt/EBITDA0.771.823.54
Interest Coverage (EBIT/Interest)11.997.187.18
Total Debt/Total Capital %15.8928.5828.72
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.